Navigation Links
Boehringer Ingelheim's Pradaxa Available in U.S. Pharmacies Starting Wednesday, November 3
Date:11/1/2010

RIDGEFIELD, Conn., Nov. 1, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co.  In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.  The 75mg dose of PRADAXA will be available in pharmacies in the coming weeks.  The U.S. Food and Drug Administration (FDA) approved PRADAXA on October 19, 2010 to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.(1)  

"The rapid availability of PRADAXA following FDA approval is a reflection of Boehringer Ingelheim's commitment to improving care for patients and their families," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "We've already received an overwhelmingly positive response from the atrial fibrillation community and we're pleased that this innovative new treatment will soon be available for patients with the condition who are at increased risk for stroke."

The wholesale acquisition price for both doses of PRADAXA will be $6.75 a day for two capsules.  PRADAXA has been in development for nearly 15 years and in the 18,113 patient, Phase III RE-LY® trial, (1) it demonstrated benefits over warfarin, the current standard of care, including a significant reduction in the risk of stroke and systemic embolism. (1)  

At Boehringer Ingelheim, the health of our patients is our first priority and we work diligently to ensure our medications are accessible and affordable for all patients. We are in active discussions with various insurance companies about
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... recommending that elderly men should not be routinely screened ... to a new study led by researchers at Henry ... online in JAMA Internal Medicine , focused on ... test for prostate cancer., "We found that the effect ... elderly men in particular has been minimal at best," ...
(Date:9/18/2014)... 2014 With the swift industrial development ... such as smart phones, tablets and PDAs, a complete ... mobile devices are viewed these days. From only being ... becoming a mode for creating and delivering content while ... way. , The complete makeover of this ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A sold-out ... community advocates, and volunteers supported United Way of ... Chefs and Fine Wines” event Monday, Sept. 15. Proceeds ... health initiatives in Westchester and Putnam, such as providing ... steering teens away from risky behaviors like drug and ...
Breaking Medicine News(10 mins):Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3
... people who have optic nerve damage might be at ... the study researchers involved 25 people with visual impairment. ... days, and their results were compared with those of ... that those with optic nerve disease were 20-times more ...
... inflammation of the liver and can cause complications such ... the hepatitis B vaccine is recommended for infants. Previous ... against infection for up to 10 years. However, a ... 10 years. ,Researchers followed eight-hundred-and-forty-one Alaska natives vaccinated ...
... of the expectant mother. Now a new study suggests ... of preeclampsia in the pregnant women. ,The ... with periodontitis with atherosclerosis to preeclampsia. Such an oral ... abuse like smoking, etc. The basic reason for setting ...
... and vitamin B12 are safe and effective in reducing the ... a stroke . According to researchers stroke patients have a ... healthy peers due to higher levels of plasma homocysteine in ... of hip fracture. ,The study was initiated to ...
... in Japan, even after the country has banned the shots of ... of the must-have vaccines to be given to children before they ... journal Lancet in 1998 had published a paper relating the MMR ... there had been considerable fall in vaccinating children with MMR (Measles, ...
... benefits of alcohol consumption and cardiovascular disease researchers studied ... // moderate levels of alcohol (one to seven drinks ... eight drinks per week), and did not consume any ... first to focus on the association between alcohol intake ...
Cached Medicine News:
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: